HK Stock Market Move | SUNSHINE PHARMA (06887) rose more than 7% and established a partnership fund with three parties to deeply integrate resources along the entire bio-pharmaceutical and health industry chain.

SUNSHINE PHARMA (06887) rose more than 7%, rising 7.64% to HK $38.06 at the time of publication, with a turnover of HK $115.77 million. On the news front, SUNSHINE PHARMA announced that on June 26, 2026, the company (as a limited partner), Guangdong Hec Technology Holding (as a general partner), and Zhejiang Guangdong Hec Technology Holding (as a limited partner) signed a partnership agreement to jointly establish a venture capital fund. The venture capital fund will mainly focus on equity investments in projects and/or sub-funds in the fields of medical health, biomedicine, and artificial intelligence. The announcement stated that participating in the establishment of the venture capital fund will deeply leverage the company's existing biomedical and health industry chain resources: firstly, by investing in high-quality venture capital sub-funds through the mother fund, it will connect with cutting-edge start-up projects, research institutes, and industry talents, early lock in innovative drugs, biomedicine intelligence, and other high-quality targets, incubating pipeline projects for the company's main business and supplementing the reserve for external mergers and acquisitions; secondly, relying on the artificial intelligence investment layout, empower the company's production digitization, research and development intelligent transformation, reduce costs and increase efficiency; thirdly, leveraging the industrial capital platform to achieve industry-investment synergy, expand the company's diversified income channels, optimize profit structure, and assist in the group's long-term industrial upgrading and ecosystem development.